Shanghai Juncell Therapeutics
20
14
14
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 20 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
A Phase II Study of GC101 in NSCLC
Role: lead
A Study of TIL in Advanced Solid Tumors (CZ)
Role: lead
A Study of GC101 TIL in Advanced Melanoma (BZ)
Role: lead
A Study of GC203 TIL in PDCA (RJ)
Role: lead
A Study of GC203 TIL in Advanced Solid Tumors (NF)
Role: lead
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
Role: lead
A Study of GC101 TIL in Advanced Melanoma
Role: lead
A Study of TIL in Advanced Solid Tumors (DFGD)
Role: lead
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Role: lead
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
Role: lead
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
Role: lead
A Study of GC101 TIL in Advanced Solid Tumors (TR)
Role: lead
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Role: lead
A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)
Role: lead
Study of GC101 TIL in Brain Glioma (Soochow2)
Role: lead
A Phase Ib Study of GC101 in NSCLC
Role: lead
A Study of GC101 TIL in Advanced Melanoma (10hospital)
Role: lead
A Phase I Study of GC101 TIL in Advanced Solid Tumors
Role: lead
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
Role: lead
Study on TIL for the Treatment of r/r Gynecologic Tumors
Role: collaborator
All 20 trials loaded